Catalyst Wire Dossier Catalyst Wire Dossier

Glycopyrronium (glycopyrrolate) - Seebri Neohaler

glycopyrronium · Novartis
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Glycopyrronium (glycopyrrolate) - Seebri Neohaler, covering 2016-02-15 to 2016-02-15. Get the full timeline:

Most recent: Clinical Trial Update: A 12-week Study to Evaluate the Efficacy and Safety of Umeclidinium 62.5 Microgram (mcg) Compared With Glycopyrronium 44 mcg in Subjects With Chronic Obstructive Pulmonary Disease (COPD) [Phase 4]

See pricing